Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

15.1K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.1K
Blood Transfusion01:15

Blood Transfusion

2.5K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.5K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards a bioengineered airway: advances in tracheal tissue engineering and biofabrication.

Frontiers in cell and developmental biology·2026
Same author

Degrading Resistance on Command: LAMP-D Reframes Targeted Protein Degradation as a Photochemical Problem.

ChemMedChem·2026
Same author

Possible Association of Disturbances in the Estrous Cycle with Anxiety-related Behavior in Aluminum-exposed Female Rats.

Annals of African medicine·2026
Same author

Emerging Utility of Artificial Intelligence Driven Medical Robots in Health Care: A Review.

Current pharmaceutical design·2026
Same author

Association of procalcitonin levels with multidrug-resistant bloodstream infections: a prospective cohort study.

BMC infectious diseases·2026
Same author

Nourishing futures: Assessing nutritional health among children under-five years of age belonging to a particularly vulnerable tribal community in Southern India.

PloS one·2026

Related Experiment Video

Updated: Feb 24, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.9K

PAI-1 Study in Thalassemia Major Patients Receiving Multiple Blood Transfusion.

Ashwini Kumar1, H S Batra2, Mithu Banerjee3

  • 1Department of Biochemistry, Air Force Hospital, Jorhat, Assam 785005 India.

Indian Journal of Clinical Biochemistry : IJCB
|August 17, 2017
PubMed
Summary

Thalassemia patients receiving blood transfusions show elevated levels of Plasminogen Activator Inhibitor-1 (PAI-1), indicating a procoagulant status. This finding suggests PAI-1 may serve as a marker for thrombotic risk in thalassemia major.

Keywords:
Hypercoagulable stateMultiple blood transfusionPAI-1Thalassemia major

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K

Related Experiment Videos

Last Updated: Feb 24, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K

Area of Science:

  • Hematology
  • Molecular Biology
  • Cardiovascular Medicine

Background:

  • Thalassemia is a congenital hemolytic anemia requiring frequent blood transfusions.
  • Chronic iron overload and procoagulant status are significant complications in thalassemia patients.
  • Procoagulant status contributes to thrombotic events in individuals with thalassemia.

Purpose of the Study:

  • To investigate the procoagulant status in thalassemia major patients.
  • To evaluate Plasminogen Activator Inhibitor-1 (PAI-1) as a marker for hypercoagulability in thalassemia.
  • To assess the correlation between PAI-1 levels and the cumulative number of blood transfusions.

Main Methods:

  • A case-control study involving 30 thalassemia major patients on regular blood transfusions and 30 healthy controls.
  • Measurement of serum PAI-1 levels in both groups.
  • Statistical analysis to compare PAI-1 levels between cases and controls and to assess correlations.

Main Results:

  • Thalassemia major patients exhibited significantly higher mean PAI-1 levels (3683 ± 358 pg/ml) compared to healthy controls (3047 ± 414 pg/ml) (p < 0.05).
  • PAI-1 levels showed a positive correlation with the total number of blood transfusions received by the patients.
  • These findings indicate an increased procoagulant state in thalassemia major.

Conclusions:

  • Elevated PAI-1 levels in thalassemia major patients suggest a hypercoagulable state.
  • PAI-1 may serve as a valuable biomarker for assessing thrombotic risk in transfusion-dependent thalassemia.
  • Further research is warranted to explore the clinical implications of PAI-1 levels in managing thalassemia complications.